Abvc Biopharma, INC 8-K filings

ABVC BioPharma and its subsidiary BioLite have amended their licensing agreement with AiBtl BioPharma, allowing for incremental payments of a $3.5 million milestone.

ABVC BioPharma and its co-development partner, BIOFIRST, have amended their licensing agreement with ForSeeCon Eye Corporation, allowing for incremental payments of a $3.5 million milestone.

ABVC BioPharma has entered into a definitive agreement with OncoX BioPharma to develop and commercialize a novel combination therapy for Myelodysplastic Syndrome (MDS), potentially revolutionizing treatment and improving patient outcomes.

ABVC BioPharma has entered into an agreement with Lind Global Fund II, LP, resulting in the exercise of existing warrants for $750,000 and the issuance of new warrants.

ABVC BioPharma has terminated an agreement to acquire land in Taiwan from a company director, citing the best interests of the company and its shareholders.

ABVC BioPharma and OncoX BioPharma have entered into a licensing agreement to develop and commercialize a combination therapy for Triple Negative Breast Cancer, potentially generating $13.75 million in income and up to $12.5 million in royalties.

ABVC BioPharma and OncoX BioPharma have entered into a licensing agreement to develop and commercialize ABVC's BLEX 404 for pancreatic cancer treatment, with ABVC expecting up to $26.25 million in income and royalties.

ABVC BioPharma successfully held its 2024 annual meeting, re-electing all 11 directors and approving the ratification of its accounting firm, the issuance of shares related to convertible notes, and an increase to its equity incentive plan.

ABVC BioPharma has granted OncoX exclusive rights to develop and commercialize its Maitake Mushroom extract for Non-Small Cell Lung Cancer in North America, expecting $13.75 million in income and potential royalties.

ABVC BioPharma and BioFirst Corporation have entered into a global licensing agreement with ForSeeCon Eye Corporation for their ophthalmology pipeline, including Vitargus, potentially earning up to $93.5 million in licensing fees and royalties.

ABVC BioPharma has amended its bylaws to reduce the quorum requirement for shareholder meetings from a majority to 33-1/3% of the votes entitled to be cast.

ABVC BioPharma announced its 2023 annual financial results, highlighting strategic investments, licensing deals, and progress in clinical trials.

ABVC BioPharma amended its convertible note agreement with Lind Global Fund II, LP, establishing a floor price for conversion and a cash payment mechanism under certain conditions.

ABVC BioPharma amended its convertible note with Lind Global Fund II, LP, establishing a $1.00 floor price for conversions and a potential cash payment to Lind if the floor price is triggered.

ABVC BioPharma has entered into a definitive agreement to acquire land in Taiwan valued at approximately $2.96 million through an equity transfer, aiming to establish a base for botanical drug development.

ABVC BioPharma files an amendment to its previous 8-K report to include audited financials of AIBL BioPharma, which it acquired a controlling interest in, and pro forma combined financials.

ABVC BioPharma has amended the terms of a convertible note and disclosed the issuance of warrants to the placement agent, Allele Capital Partners, LLC.

ABVC BioPharma's 2024 Annual Meeting of Shareholders was adjourned due to the company not achieving a quorum.

ABVC BioPharma has entered into a securities purchase agreement with Lind Global Fund II, LP, resulting in a $1 million secured convertible note offering.